Novartis: Carcinoma, Renal Cell trials

The registry lists 38 Carcinoma, Renal Cell studies with Novartis as lead sponsor. 0 are open to participants now and 17 have results posted.

Phase 1 14Phase 2 13Phase 3 5Phase 4 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaTerminatedNCT03207867Phase 2Results posted
• Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor TreatmentCompletedNCT03200717Phase 2Results posted
• Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesTerminatedNCT02608268Phase 1/2Results posted
• Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell CarcinomaTerminatedNCT01545817Phase 2Results posted
• Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or PazopanibCompletedNCT01514448Phase 4Results posted
• Everolimus as Second-line Therapy in Metastatic Renal Cell CarcinomaCompletedNCT01491672Phase 2Results posted
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)CompletedNCT01235962Phase 3Results posted
• Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell CarcinomaCompletedNCT01223027Phase 3Results posted
• A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.CompletedNCT01206764Phase 4Results posted
• Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell CarcinomaCompletedNCT01147822Phase 2Results posted
• Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney CancerCompletedNCT01064310Phase 3Results posted
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell CarcinomaCompletedNCT00903175Phase 2Results posted
• Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell CarcinomaCompletedNCT00720941Phase 3Results posted
• Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney CancerCompletedNCT00719264Phase 2Results posted
• RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in EuropeCompletedNCT00688753Phase 2Results posted
• Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic MelanomaCompletedNCT00414765Phase 4Results posted
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or SunitinibCompletedNCT00410124Phase 3Results posted
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid TumorsTerminatedNCT05462873Phase 1
• DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesTerminatedNCT04895748Phase 1
• Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal CancersCompletedNCT03798626Phase 1
• A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.TerminatedNCT03549000Phase 1
• HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell CarcinomaTerminatedNCT02947152Phase 1
• A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
• Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic TumorsCompletedNCT02077933Phase 1
• Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)CompletedNCT02014636Phase 1
• Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell CarcinomaCompletedNCT01689766Phase 2
• Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell CarcinomaCompletedNCT01689662Phase 2
• Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell CarcinomaCompletedNCT01649778
• Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid TumorsCompletedNCT01482156Phase 1
• A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of AfinitorCompletedNCT01390519
• Safety of RAD001 in Chinese Patients With Metastatic Renal Cell CancerCompletedNCT01152801Phase 1
• A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell CancerCompletedNCT00715182Phase 1
• Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor TherapyNo longer availableNCT00655252
• A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell CarcinomaTerminatedNCT00485563Phase 2
• Study To Assess Long Term Safety Of PazopanibCompletedNCT00387205Phase 1
• Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone MetastasisCompletedNCT00172003Phase 4
• Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2